Darryle D. Schoepp PhD

Dr. Schoepp has over thirty years of experience in the discovery and development of innovative Neuroscience therapeutics in the pharmaceutical industry. This includes 20 years at Eli Lilly as a scientist and leader of the Neuroscience research department and 12 years at Merck as the Neuroscience research therapeutic area leader.

As head of Neuroscience Research at Merck (2007-2018), his team built a pipeline of innovative first-class agents for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia. Merck Neuroscience successfully developed and launched the first in class orexin receptor antagonist Suvorexant (Belsomra) for insomnia and created the novel first-in-class oral CGRP antagonists ubrogepant and atogepant currently in registration trials for migraine treatment and prevention (by Allergan). His group made important contributions to the pioneering trials of the BACE inhibitor verubecestat in prevention trials for Alzheimer’s disease. Most recently the Merck group advanced a promising novel mechanism through efficacy trials for schizophrenia.